Therefore, for effective prevention of colorectal cancer progression, selective inhibition of FGFR3-IIIc, WNT or MAPK and PI3K/AKT signaling pathways in CRC cells, as well as selective targeted therapy of CD44-positive subsets of CRC cells can be used. This evidence concerns the gene CD44 and colorectal carcinoma.